Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Eli Lilly chairman and CEO David Ricks joins CNBC’s “Squawk on the Street” team to discuss its quarterly earnings report that ...

The instant success of weight loss drugs in India tells us how quickly the country is changing. And for once, the change is ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

The company sees no supply constraints for tirzepatide, a concern that has plagued other players in the GLP-1 space globally.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Meghan Trainor showed off her flat abs in a mirror selfie with coach Bella Maher after the pop star went through a weight ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...